Pigment Epithelium–derived Factor in Idiopathic Pulmonary Fibrosis

Gregory P. Cosgrove(National Jewish Health), G. Scott Worthen(Children's Hospital of Philadelphia), Mark W. Geraci(Indiana University School of Medicine), Marvin I. Schwarz(San Francisco General Hospital), Carlyne D. Cool(University of Colorado Anschutz Medical Campus), Jane E. Parr(National Jewish Health), Amanda E. Serls(National Jewish Health), William P. Schiemann(Case Western Reserve University), Kevin K. Brown(Health Protection Surveillance Centre)
American Journal of Respiratory and Critical Care Medicine
May 3, 2004
10.1164/rccm.200308-1151oc
Cited by 260

Related Papers

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
|New England Journal of Medicine|2011|1.1k
Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2003|762
A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
|New England Journal of Medicine|2004|652
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
|The Lancet Respiratory Medicine|2020|558